With U.S. headquarters in Seattle, WA, Orange Biomed was launched in 2021 by Duke University alumnus Dr. Unghyeon Ko and Yeaseul Park to solve unmet diabetes-focused healthcare needs. The healthcare startup innovates cutting-edge technology for diabetes management, including OBM rapid A1c.
The global impact of OBM rapid A1c was recognized in 2024 when the Korean Hospital Association honored it with the prestigious KHF Innovation Award for its revolutionary application of microfluidic technology conducting single-cell analysis.
In 2025 and beyond, Orange Biomed is focused on bringing OBM rapid A1c to U.S. patient-oriented healthcare. The company is preparing a 510(k) submission to the FDA for potential over-the-counter (OTC) clearance of its product, followed by a point-of-care (POC) application submission, further expanding access to innovative diabetes care solutions and more.
Company Details
- Employees
- 11
- Founded
- -
- Address
- 1730 Minor Ave,
- Industry
- Medical Device
- Website
- https://www.orangebiomed.com/
- HQ
- Seattle, Washington
Orange Biomed Questions
Orange Biomed's website is https://www.orangebiomed.com/
Orange Biomed's LinkedIn profile is https://www.linkedin.com/company/orangebiomed
Orange Biomed has
11 employees.
View email and phone details for 11
employees at Orange Biomed.
Orange Biomed's industry is
Medical Device
Orange Biomed's top competitors are
Diabeteswise,
Diatech Diabetes, Inc.,
Replica Health,
Dreamed,
Glaice,
Ryse Health,
Mediwhale,
Mobileodt,
Virta Health,
Bioaesthetics.
Orange Biomed's categories are Medical Device
Orange Biomed's founding year is 2021
